Podcasts about fda approval

university texas education fda california irvine fda approval kimberly brown

Play Episode Listen Later Jun 4, 2025 1:11

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Roche and Jazz Pharmaceuticals presented data at ASCO showing that their drug combination improved survival in a phase III lung cancer trial, with analysts noting a strong treatment effect. Jazz has filed for FDA approval for the combination, which could provide an alternative to monotherapy treatments from Roche and AstraZeneca. Trump's tariffs could potentially endanger the rare disease space, according to industry experts. Other news includes Kymera's success with a protein degrader candidate, Amgen's IMDelltra boosting survival in small cell lung cancer, and concerns about the impact of FDA guidelines on nitrosamine testing. BioAgilytix will be at BIO International to discuss their drug production capabilities. Other news includes Kura's new data in acute myeloid leukemia, Keros' layoffs, Regeneron's investment in a Chinese obesity drug, and Sanofi's acquisition of Blueprint to expand their rare disease portfolio. Upcoming events include webinars on AI in life science R&D and the crisis facing the pharma industry. Job opportunities in clinical data management, regulatory affairs, and scientific roles are also highlighted.

SSO Education: FDA Approval of Lifileucel

SurgOnc Today

Play Episode Listen Later May 30, 2025 17:26

In this episode, Dr. Kimberly Brown from The University of Texas at Austin Dell Medical School moderates a discussion with Dr. Thuy Tran from the University of California Irvine about the FDA approval of Lifileucel.

S13 Ep6: FDA Approval Insights: Perioperative Durvalumab Plus Chemo in MIBC: With Matthew Galsky, MD

MedEvidence! Truth Behind the Data

Play Episode Listen Later May 28, 2025 7:48

In today's episode, we spoke with Matthew Galsky, MD, about the FDA approval of neoadjuvant durvalumab (Imfinzi) plus gemcitabine and cisplatin followed by adjuvant durvalumab monotherapy after radical cystectomy for the treatment of adult patients with muscle-invasive bladder cancer (MIBC). Dr Galsky is a professor of medicine (hematology and medical oncology), a professor of urology, director of Genitourinary Medical Oncology, co-director of the Center of Excellence for Bladder Cancer, and director for Translational Research at The Tisch Cancer Institute in New York, New York. In our exclusive interview, Dr Galsky discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 NIAGARA trial (NCT03732677), and the role of this regimen in the MIBC treatment paradigm, including for cisplatin-eligible patients with mild renal impairment.

new york md excellence fda niagara chemo fda approval translational research perioperative bladder cancer mibc genitourinary medical oncology

FDA Approval: Telisotuzumab Vedotin and MET-Positive NSCLC

Lung Cancer Considered

Play Episode Listen Later May 27, 2025 33:15

In this episode, we will discuss the FDA approval of telisotuzumab vedotin, an antibody drug conjugate, for NSCLC with high c-MET expression. To help review the data and offer perspective on this new agent, I am joined by two expert thoracic oncologists. I want to welcome Dr. Mor Moskovitz, Head of the Thoracic Medical Oncology Service at Davidoff Cancer Center at the Rabin Medical Center in Petah Tikva, Israel.

head israel positive fda fda approval nsclc

Insider Look at Rabacfosadine (Tanovea) from Shelved Human Drug to Dog Lymphoma Treatment | Dr. Doug Thamm #284

Dog Cancer Answers

Play Episode Listen Later May 26, 2025 50:53

Dr. Doug Thamm discusses the development and use of Tanovea, a drug for treating lymphoma in dogs. He explains the drug's origins, initially researched as a human cancer therapeutic in collaboration with Gilead Sciences, and its transition to veterinary use. Dr. Thamm provides insights into Tanovea's application, dosage, and effectiveness compared to the CHOP protocol, as well as its potential side effects and other possible uses in different cancer types like multiple myeloma. The episode also delves into related immunotherapy research and personal reflections from Dr. Thamm, a double cancer survivor, on his career choice in veterinary oncology. Your Voice Matters! If you have a question for our team, or if you want to share your own hopeful dog cancer story, we want to hear from you! Go to https://www.dogcancer.com/ask to submit your question or story, or call our Listener Line at +1 808-868-3200 to leave a question. Related Videos: https://www.youtube.com/watch?v=G0iRyKshzq8 Related Links: Our article on lymphoma: https://www.dogcancer.com/articles/types-of-dog-cancer/lymphoma-in-dogs/ Our article on Tanovea: https://www.dogcancer.com/articles/drugs/tanovea-rabacfosadine-chemotherapy/ Get the facts on dog cancer remission: https://www.dogcancer.com/articles/stats-and-facts/dog-cancer-remission/ Chapters: 00:00 Introduction 00:13 Interview with Dr. Doug Thamm 00:26 The Early Involvement with Tanovea 00:41 Challenges and Discoveries in Drug Development 02:16 Transition from Human to Veterinary Use 02:48 Clinical Trials and Dosage Experiments 06:45 FDA Approval and Practical Use 08:05 Comparing Tanovea and CHOP Protocol 15:23 Exploring Alternative Treatments: Laverdia 18:43 Off-Label Uses and Future Research 23:46 Exploring Tanovea's Effectiveness in Blood Cancers 25:14 Cost Comparison: Tanovea vs. CHOP 26:15 Side Effects of Tanovea 28:47 Pulmonary Fibrosis and Breed-Specific Risks 32:52 Personal Cancer Journeys: Dr. Doug and His Wife 38:23 Debunking Myths About Dog Cancer Treatment 42:24 The Future of Cancer Treatment: Immunotherapy 45:23 Conclusion and Resources Get to know Dr. Doug Thamm: https://www.dogcancer.com/people/doug-Thammm-v-m-d-diplomate-acvim-oncology/ For more details, articles, podcast episodes, and quality education, go to the episode page: https://www.dogcancer.com/podcast/ Learn more about your ad choices. Visit megaphone.fm/adchoices

Play Episode Listen Later May 19, 2025 8:44 Transcription Available

Send us a textThe FDA has granted full approval to Novavax's COVID-19 vaccine, providing an alternative to mRNA vaccines that works through a different mechanism using proteins and adjuvants. Despite being four years into the pandemic, COVID-19 remains a significant health concern, causing approximately 1 in 200 deaths in the US in 2025.• Novavax uses bioengineered spike proteins combined with an adjuvant rather than mRNA technology• FDA approved Novavax for all Americans over 65 and those 12-64 with at least one risk factor• Risk factors include conditions like asthma, diabetes, and obesity• Northeast Florida contributed 500 patients to the original Novavax clinical trials• Encore Research Group is currently enrolling participants for an oral COVID vaccine clinical trial• Participants in the oral vaccine trial will receive compensation for their timeFor more information about participating in the oral COVID vaccine study, visit EncoreDocs.com or call 904-730-0101.Be a part of advancing science by participating in clinical research.Have a question for Dr. Koren? Email him at askDrKoren@MedEvidence.comListen on SpotifyListen on Apple PodcastsWatch on YouTubeShare with a friend. Rate, Review, and Subscribe to the MedEvidence! podcast to be notified when new episodes are released.Follow us on Social Media:FacebookInstagramX (Formerly Twitter)LinkedInWant to learn more? Checkout our entire library of podcasts, videos, articles and presentations at www.MedEvidence.comMusic: Storyblocks - Corporate InspiredThank you for listening!

covid-19 americans risk fda checkout mrna clinical trials health podcast novavax fda approval northeast florida

This Founder Just Got FDA Approval For The First-Ever At-Home Cervical Cancer Screening Tool

Forbes Newsroom

Play Episode Listen Later May 16, 2025 13:47

The FDA has granted approval to Teal Health's at-home cervical cancer screening wand, the first self-collection tool for HPV screening in the U.S. Kara Egan, the cofounder and CEO of Teal Health, joined ForbesWomen editor Maggie McGrath talk about this milestone and what happens next.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

ceo founders politics news debate forbes congress republicans democrats controversy senate fda hpv cancer screenings fda approval cervical cancer screening screening tool

Pharma and Biotech Daily: Breaking News and Innovations in Healthcare

covid-19 news innovation healthcare journal collaboration alzheimer's disease breakthrough delta breaking news pharma biotech oncology delta variant cancer treatment fda approval vaccine update

Play Episode Listen Later May 15, 2025 2:31

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. ## Breakthrough in Cancer TreatmentIn a groundbreaking study published in the Journal of Oncology, researchers have discovered a new combination of drugs that has shown promising results in treating pancreatic cancer. The study, which involved over 500 patients, found that the combination of drug A and drug B was able to significantly shrink tumors in over 70% of patients. This discovery has the potential to revolutionize the way we treat pancreatic cancer and could lead to improved outcomes for patients in the future.## FDA Approves New Drug for Alzheimer's DiseaseThe FDA has approved a new drug for the treatment of Alzheimer's disease, marking a major milestone in the fight against this devastating condition. The drug, which works by targeting the underlying causes of Alzheimer's, has shown promising results in clinical trials and is now available to patients across the country. This approval represents a significant step forward in our understanding of Alzheimer's disease and offers hope to the millions of people affected by this condition.## Vaccine Update: Delta VariantWith the rise of the Delta variant, there has been growing concern about the effectiveness of existing vaccines against this strain of the virus. However, recent studies have shown that current vaccines are still highly effective at preventing severe illness and hospitalization caused by the Delta variant. While breakthrough infections may occur, the vaccines are still providing robust protection against the worst outcomes of COVID-19. This is reassuring news as we continue to navigate the ongoing pandemic.## Collaboration Leads to New Drug DevelopmentA collaboration between two pharmaceutical companies has resulted in the development of a new drug for the treatment of rare genetic disorder. By pooling their resources and expertise, the two companies were able to accelerate the drug development process and bring this much-needed treatment to market sooner than would have been possible on their own. This successful collaboration serves as a model for future partnerships in the pharmaceutical industry and highlights the importance of working together to advance medical research.## ConclusionIn conclusion, these recent developments in cancer treatment, Alzheimer's disease, vaccine effectiveness, and collaborative drug development represent significant advances in the field of Pharma and Biotech. With ongoing research and innovation, we can look forward to more breakthroughs that will improve patient outcomes and change the landscape of healthcare. Thank you for listening to Pharma and Biotech daily, where we bring you the latest news and updates from the world of pharmaceuticals and biotechnology.

Perioperative Durvalumab FDA Approval New Standard for Muscle Invasive Bladder Cancer

comparison fda muscle gu invasive niagara new standard fda approval perioperative bladder cancer ctdna

Play Episode Listen Later May 5, 2025 21:58

Welcome to another episode of the Oncology Brothers podcast! In this episode, we dived into the recent FDA approval of Durvalumab combined with chemotherapy for resectable muscle-invasive bladder cancer, based on the NIAGARA trial. Join us as we chat with Dr. Thomas Powles, a GU medical oncologist and the lead author of the NIAGARA trial. We discussed the study design, the significant improvements in overall survival, and the implications of this new treatment approach. Dr. Powles shared insights on the use of immunotherapy in the perioperative setting, the importance of pathological complete response, and the safety of combining Durvalumab with chemotherapy. Key topics covered in this episode: •⁠ ⁠Overview of the NIAGARA trial and its findings •⁠ ⁠Comparison of Durvalumab and cisplatin-based chemotherapy outcomes •⁠ ⁠The significance of event-free survival and overall survival rates •⁠ ⁠Insights on managing side effects and treatment sequencing •⁠ ⁠The evolving role of ctDNA in determining treatment strategies YouTube: https://youtu.be/s_tXoX5yhV8 Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Tune in to learn how these advancements are changing the landscape of bladder cancer treatment and improving patient outcomes. Don't forget to like, subscribe, and check out our other episodes for more insights on oncology and FDA approvals! #OncologyBrothers #BladderCancer #Dervalumab #FDAApproval #NiagaraTrial #Immunotherapy #CancerResearch #OncologyPodcast

Indies Pharma Stock Analysis: Their Secret Plan to DOUBLE Revenue

Limitless

Play Episode Listen Later May 2, 2025 81:15

In this episode of Tickers, Dr. Matthew Preston & Dr. Thaon Simms analyze Indies Pharma (INDIES) and its potential to reach $5 per share!

drop caribbean stock fda revenue jamaican limitless pharma stay connected indies pharmaceutical industry fda approval secret plan generic drugs jse tickers limitless podcast matthew preston

Episode 128. Ensifentrine (Ohtuvayre) for COPD: 2024 FDA Approval, ENHANCE Trials, and What You Need to Know

MedCram

Play Episode Listen Later May 1, 2025 12:46

Roger Seheult, MD of MedCram explains a new FDA approved medication for COPD and the ENHANCE trials. See all Dr. Seheult's videos at: https://www.medcram.com/ (This video was recorded on April 28th, 2025) Roger Seheult, MD is the co-founder and lead professor at https://www.medcram.com He is Board Certified in Internal Medicine, Pulmonary Disease, Critical Care, and Sleep Medicine and an Associate Professor at the University of California, Riverside School of Medicine. MEDCRAM WORKS WITH MEDICAL PROGRAMS AND HOSPITALS: MedCram offers group discounts for students and medical programs, hospitals, and other institutions. Contact us at customers@medcram.com if you are interested. MEDIA CONTACT: Media Contact: customers@medcram.com Media contact info: https://www.medcram.com/pages/media-c... Video Produced by Kyle Allred FOLLOW US ON SOCIAL MEDIA: https://www.facebook.com/MedCram https://twitter.com/MedCramVideos https://www.instagram.com/medcram DISCLAIMER: MedCram medical videos are for medical education and exam preparation, and NOT intended to replace recommendations from your doctor. #COPD #FDA #Ensifentrine

Diabetes Dialogue: Semaglutide for MASH in ESSENCE Trial, With Arun Sanyal, MD

Diabetes Dialogue: Therapeutics, Technology, & Real-World Perspectives

Play Episode Listen Later Apr 30, 2025 25:35

Video Version Only on HCPLive! In this episode of Diabetes Dialogue: Technology, Therapeutics, and Real-World Perspectives, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, and Natalie Bellini, DNP, program director of Diabetes Technology at University Hospitals Diabetes and Metabolic Care Center, break down new Phase 3 data from the ESSENCE trial examining semaglutide 2.4 mg (Wegovy) for metabolic dysfunction-associated steatohepatitis (MASH) with stage 2 or 3 fibrosis. With results published in The New England Journal of Medicine, hosts are joined by first author Arun J. Sanyal, MD, director of the Stravitz-Sanyal Institute for Liver Disease and Metabolic Health at Virginia Commonwealth University, to discuss key takeaways from part 1 of the ESSENCE trial, semaglutide's impact on liver outcomes and weight loss, and what the data could mean for the future of MASH treatment. ESSENCE Once-weekly semaglutide 2.4 mg significantly improved liver outcomes in patients with metabolic dysfunction–associated steatohepatitis (MASH) and stage 2 or 3 fibrosis, according to findings from the ESSENCE trial. In part 1 of the ongoing, double-blind, placebo-controlled trial, 800 patients were evaluated at 72 weeks for two primary endpoints: resolution of steatohepatitis without worsening fibrosis, and fibrosis improvement without worsening steatohepatitis. Spanning 253 sites in 37 countries, the full trial enrolled 1197 biopsy-confirmed patients between May 2021 and April 2023. At the interim analysis, semaglutide achieved both primary endpoints. Resolution of steatohepatitis without fibrosis worsening occurred in 62.9% of patients receiving semaglutide compared with 34.3% in the placebo group (difference, 28.7%; 95% CI, 21.1–36.2; P

Turning Customers into Investors and Transforming Start-up Financing

The Angel Next Door

Play Episode Listen Later Apr 17, 2025 32:30

How does crowdfunding fit into a startup's fundraising strategy? In this intriguing episode of The Angel Next Door Podcast, host Marcia Dawood converses with guest Woodie Neiss about how crowdfunding has emerged as a transformative option for entrepreneurs seeking capital. The conversation unveils the ways securities-based crowdfunding is reshaping how new ventures are funded, making investments more accessible to various investors.Woodie Neiss, an experienced entrepreneur and a key advocate for crowdfunding legislation, shares his journey from Wall Street to becoming a pivotal figure in changing securities laws. His efforts have helped launch a thriving crowdfunding industry that offers over $2.8 billion in raised capital to more than 8,000 startups. He is also one of the founders of Crowdfund Capital Advisors (CCA), a crowdfunding advisory, implementation, and education firm.This episode is a must-listen for anyone involved in entrepreneurship, providing insights into significant crowdfunding developments and statistics. Woodie discusses how the industry has evolved, highlighting trends in sectors like healthcare and technology, and explaining how crowdfunding complements traditional fundraising strategies. Whether you're an investor, entrepreneur, or policymaker, this episode offers valuable perspectives on the current and future state of investment crowdfunding. To get the latest from Woodie Neiss, you can follow him below!https://www.linkedin.com/in/sherwoodneiss/https://crowdfundcapitaladvisors.com/https://a.co/d/f9987We - Investomers: How Customers-Turned-Investors are Shaping the Future of Early-Stage Finance Sign up for Marcia's newsletter to receive tips and the latest on Angel Investing!Website: www.marciadawood.comLearn more about the documentary Show Her the Money: www.showherthemoneymovie.comAnd don't forget to follow us wherever you are!Apple Podcasts: https://pod.link/1586445642.appleSpotify: https://pod.link/1586445642.spotifyLinkedIn: https://www.linkedin.com/company/angel-next-door-podcast/Instagram: https://www.instagram.com/theangelnextdoorpodcast/TikTok: https://www.tiktok.com/@marciadawood

157 | Learning Lessons Along the FDA Approval Pathway

TrainSmart: The Medical Device Educatorsâ€™ Podcast

Play Episode Listen Later Apr 15, 2025 11:13

This week, Rachel and Liz discuss Liz's conversation with Nada Hanafi on the FDA approval pathway and how training can be used to mitigate risk. They share what they learned from Nada about the process and their insights for developing curriculum that has high standards to ensure patient safety. In 2025, we're embarking on a MedDevice Training Journey: From clinical trials to standard of care. Join us all year long as we explore training at each stage of the product life cycle.Need help developing your clinical trial training strategies? Contact us at training@cumbyconsulting.com.Related Resources:Nada's interview Subscribe to our newsletter to hear more about the journey from clinical trials to standard of care! Click here to subscribe!Connect with us on LinkedIn: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cumby Consulting⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Rachel Medeiros⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Liz Cumby⁠⁠⁠⁠⁠About Cumby Consulting: Cumby Consulting's team of professionals deliver innovative MedTech training services for physicians, sales representatives, teaching faculty, key opinion leaders and clinical development teams. Whether you need a complete training system developed to deliver revenue sooner or a discrete training program for a specific meeting, Cumby Consulting will deliver highly strategic, efficient programs with uncompromising standards of quality.

fda pathway medtech fda approval learning lessons

FDA Approval of Cabozantinib - CABINET in pNET and epNET

miami fda cabinet drs rohit sequencing fda approval sylvester comprehensive cancer center cabozantinib

Play Episode Listen Later Apr 10, 2025 19:14

Welcome to another episode of the Oncology Brothers podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Aman Chauhan, a medical oncologist specializing in neuroendocrine tumors from Sylvester Comprehensive Cancer Center in Miami. As of April 2025, the oncology landscape has seen 10 new FDA approvals, including the recent approval of cabozantinib for neuroendocrine tumors based on the CABINET study. The discussion dived deep into the implications of this approval, the study design, and how cabozantinib fits into the treatment landscape for both pancreatic and extra-pancreatic neuroendocrine tumors. Key topics covered in this episode include: •⁠ ⁠The evolution of treatment options for neuroendocrine tumors •⁠ ⁠Insights into the CABINET study design and results •⁠ ⁠Sequencing treatment options for patients with neuroendocrine tumors •⁠ ⁠Side effects and management strategies for cabozantinib •⁠ ⁠The importance of personalized treatment approaches in oncology Join us as we explore the exciting advancements in neuroendocrine tumor management and what they mean for patients and oncologists alike. Don't forget to like, subscribe, and check out our other discussions on FDA approvals, toxicity management, and conference highlights! Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to like, subscribe, and hit the notification bell for more updates on oncology insights!

The First Treatment for a Rare Neurodegenerative Condition Awaits FDA Approval

RARECast

Play Episode Listen Later Apr 3, 2025 24:16

Spinocerebellar ataxia includes a group of rare, genetic, neurodegenerative disorders. People with the condition suffer from the loss of balance, coordination, and muscle control. As the condition progresses, people can lose the ability to walk and speak. There is no approved treatment for SCA, but Biohaven has applied to the U.S. Food and Drug Administration to begin marketing its experimental therapy troriluzole, which can normalize levels of glutamate, a key neurotransmitter implicated in the disease. We spoke to Melissa Beiner, senior medical director at Biohaven, about spinocerebellar ataxia, the company's therapy under review at the FDA to treat the condition, and why it may have the potential to benefit a number of other neurological conditions as well.

food treatments fda rare condition drug administration sca fda approval neurodegenerative

Pharma and Biotech Daily: Your Essential Update on the Latest Industry News

Play Episode Listen Later Apr 1, 2025 2:16

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Sanofi and Alnylam have received FDA approval for the first RNAi treatment for hemophilia, with the drug, Qfitlia, indicated for both hemophilia A and B. This approval is significant as it can be given regardless of the presence of neutralizing antibodies against clotting factors VIII or IX. However, the sudden departure of FDA director Peter Marks has caused uncertainty in the biopharma industry. In other news, Vertex has cut a diabetes asset but analysts remain optimistic about their phase III option. Lilly's RNA silencer has shown promising results in lowering a key cardiovascular biomarker. Trilink is offering custom guide RNAs for CRISPR workflow to accelerate therapy discoveries. Despite market challenges, the cell and gene therapy sector has seen a 30% investment surge. Companies like Amgen, Aldeyra, and Argenx are among those with upcoming FDA actions. Arbutus has announced layoffs, while big pharmas are pushing boundaries in radiopharmaceuticals. Michelle Werner of AltoRNA is focused on making better drugs. Safety questions are looming in Duchenne as Dyne and Wave plan FDA filings. There are job opportunities available in data management and program leadership within the biopharma industry.Moving on to other news, several big pharmaceutical companies such as Novartis, Bayer, AstraZeneca, Bristol Myers Squibb, and Eli Lilly are competing in the radiopharmaceuticals market, which is projected to be worth over $13 billion by 2033. The FDA is expected to announce decisions on therapies for dry eye disease soon. Michelle Werner, CEO of AllTrna, is focused on developing trna-based treatments for various diseases.Safety concerns are emerging in the Duchenne muscular dystrophy space as companies like Dyne and Wave plan FDA filings. The EU rejected Lilly's Alzheimer's drug Kisunla, Biontech's bispecific showed promise in treating SCLC patients, and Wave's duchenne exon-skipper reversed muscle damage in a mid-stage trial. Job opportunities within the biopharma industry were also highlighted for those interested.Thank you for tuning in to Pharma and Biotech daily - keeping you updated on all the latest news in the world of pharmaceuticals and biotechnology.

Pharma and Biotech Daily: Your Essential Dose of Industry News

Play Episode Listen Later Mar 28, 2025 0:59

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world. The Department of Health and Human Services, led by Secretary Robert F. Kennedy Jr., has revealed intentions to reduce 10,000 positions and restructure departments. The appointment of vaccine critic David Geier to investigate vaccine safety within the CDC has also been announced. Soleno has recently obtained FDA approval for a medication designed to address hyperphagia in Prader-Willi syndrome patients. Meanwhile, Johnson & Johnson's combination therapy for lung cancer has displayed encouraging outcomes. A power struggle at Aurion has resulted in Alcon taking control, amidst allegations of impeding Aurion's IPO plans. Opportunities in the biopharma industry are available at the United States Pharmacopeia, alongside updates on biopharma layoffs and industry advancements. That's all for today's episode. Stay tuned for more essential news from the world of Pharma and Biotech. Thank you for listening.

health news opportunities essential cdc fda ipo dose human services pharma biotech fda approval industry news vaccine safety alcon prader willi aurion united states pharmacopeia

S12 Ep26: FDA Approval Insights: Tislelizumab Plus Chemo in Unresectable Metastatic ESCC: With Nataliya Uboha, MD, PhD

chemo md phd rationale fda approval metastatic nataliya unresectable

Play Episode Listen Later Mar 13, 2025 9:30

In our exclusive interview, Dr Uboha discussed the significance of this approval, key efficacy and safety data from the pivotal phase 3 RATIONALE-306 trial (NCT03783442), and considerations for integrating this agent into the ESCC treatment paradigm.

Intelligent Medicine Radio for March 8, Part 2: Hope for Parkinson's

Digital Pathology Podcast

Play Episode Listen Later Mar 10, 2025 42:19

More good news about Omega-3s for heart health; Addressing early-stage dementia; When Lyme Disease doesn't respond to antibiotics; Ultra-processed food hijacks brain within days; Exosomes and adaptive deep-brain stimulation offer hope for Parkinson's; Psychologists conclude relentless “pursuit of happiness” may exhaust our brains' control centers; A common over-the-counter drug taken in pregnancy may hike offsprings' risk of ADHD.

125: Direct-to-Digital Tissue Imaging | Interview with Drs. Rao and Edwards, Muse Microscopy

Play Episode Listen Later Mar 9, 2025 20:32 Transcription Available

Send us a textWhat if we could skip glass slides altogether and go straight from fresh tissue to digital image? Muse Microscopy's SmartPath device aims to do just that, capturing diagnostic-quality images directly from fresh tissue. In this episode brought to you by Muse Microscopy, I sit down with Dr. Rao and Dr. Edwards to discuss the insights, challenges, and future of this groundbreaking technology. We explore its regulatory ramifications, change management in veterinary and human pathology, and financial feasibility. Tune in to learn why SmartPath could be a game-changer for both pathologists and patients.00:00 Introduction to SmartPath Technology00:54 Meet the Experts: Dr. Rao and Dr. Edwards01:08 FDA Approval and Implementation Plans01:35 Change Management in Pathology01:56 Training Pathologists for SmartPath03:48 Translational Tissue Banking and Clinical Applications04:29 Impact on Breast Pathology05:49 Pathologists' Reception and Adoption14:33 Financial Viability and ROI19:44 Conclusion and Future ProspectsLinks and Resources:This episode on YouTubeMuse Microscopy WebsiteSmartPath Device Demo VideoSupport the showBecome a Digital Pathology Trailblazer get the "Digital Pathology 101" FREE E-book and join us!

digital impact conclusion edwards muse change management reception imaging tissue rao pathologists fda approval free e microscopy digital pathology

Neurotech's Encapsulated Cell Technology Receives FDA Approval for Treatment of MacTel

Foundation Fighting Blindness

Play Episode Listen Later Mar 7, 2025 2:11

The technology was previously funded by the Foundation for the treatment of retinitis pigmentosa and dry age-related macular degeneration.

technology foundation treatments receives fda approval neurotech

FDA Approval of Tislelizumab - RATIONALE 305 and 306 in Upper GI Cancers

Play Episode Listen Later Mar 6, 2025 19:49

Welcome to the Oncology Brothers podcast! In this episode, Drs. Rahul and Rohit Gosain are joined by Dr. Anwaar Saeed, Chief of GI Medical Oncology at UPMC, to discuss the recent approval of Tislelizumab, a new checkpoint inhibitor for upper GI malignancies, including esophageal squamous cell cancer, GE junction, and gastric cancer. We dive deep into the studies that led to Tislelizumab's approval, including the Rationale 302, 305, and 306 trials. Dr. Saeed explains the unique mechanism of action of Tislelizumab, its higher binding affinity to PD-1, and how it compares to other PD-1 inhibitors like nivolumab and pembrolizumab. Key topics covered in this episode: •⁠ ⁠Overview of Tislelizumab and its mechanism of action •⁠ ⁠Insights from the Rationale 306 trial and its implications for frontline treatment •⁠ ⁠Discussion on the Rationale 305 trial focusing on adenocarcinoma •⁠ ⁠The importance of PD-L1 testing and biomarker-driven treatment decisions •⁠ ⁠Side effect profiles of Tislelizumab compared to other immunotherapies •⁠ ⁠Future directions in the use of immunotherapy for upper GI malignancies Join us for this informative discussion that highlights the evolving landscape of cancer treatment and the importance of precision oncology. If you find this episode helpful, please share it with your colleagues and leave us a review! YouTube: https://youtu.be/hQeLdpSzGCk Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers •⁠ Website: https://oncbrothers.com/ Don't forget to subscribe for more practice-changing discussions in the world of oncology. We are the Oncology Brothers!

future chief cancer ge gi drs pd rahul rationale saeed upmc fda approval pd l1 upper gi

S12 Ep22: FDA Approval Insights: Vimseltinib for Symptomatic TGCT: With William D. Tap, MD

Play Episode Listen Later Mar 6, 2025 7:48

Dr Tap discusses the significance of the FDA approval of vimseltinib for symptomatic TGCT, in which surgical resection may worsen functional limitation or cause severe morbidity. He also discussed key efficacy and safety data from the pivotal phase 3 MOTION trial and the increasingly important role that multidisciplinary collaboration will play as this targeted therapy is further integrated into clinical practice.

fda tap motion fda approval symptomatic tgct william d tap

Beyond Boundaries: Pioneering Medical Innovations, Part 2

Play Episode Listen Later Mar 5, 2025 40:37

Dr. Hoffman continues his conversation with Dr. Kieran Murphy, author of “The Essence of Invention: Medicine and the Joy of Creativity,”

Beyond Boundaries: Pioneering Medical Innovations, Part 1

Play Episode Listen Later Mar 5, 2025 28:57

In this episode of the Intelligent Medicine podcast, Dr. Ronald Hoffman interviews Professor Kieran Murphy, an interventional neuro radiologist and prolific inventor from Toronto Western Hospital. Dr. Murphy has developed numerous innovative medical devices and filed 60 patents. He shares insights from his book, “The Essence of Invention: Medicine and the Joy of Creativity,” discussing his work on medical innovation, his unique background, and personal experiences that have driven his creative solutions. The conversation covers various topics, including the importance of creativity, the impact of bureaucracy on modern medicine, and groundbreaking innovations like ozone therapy for herniated discs and a radio-protective supplement for medical personnel. Dr. Murphy emphasizes mindfulness and paying attention to phenomena as key components for fostering creativity and innovation in medicine.

Pharma and Biotech Daily: Reshoring, Setbacks, and Successes

donald trump news fda pfizer setbacks manufacturing astrazeneca pharma successes biotech roche clinical trials eli lilly fda approval reshoring atara daiichi sankyo enhertu

Play Episode Listen Later Mar 5, 2025 0:39

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Pfizer and Eli Lilly are considering reshoring manufacturing in the U.S. in response to President Trump's tariff threats. Biohaven faces setbacks in clinical trials, while Roche gains FDA approval for a stroke drug expansion. Startup Delphia aims to use a precision medicine approach to target cancer cells. Industry leaders will discuss orphan drug development at the World Orphan Drug Congress 2025. Other news includes Beigene's label expansion, AstraZeneca and Daiichi Sankyo's success with Enhertu in stomach cancer, and Atara's restructuring.

S12 Ep20: FDA Approval Insights: Sotorasib Plus Panitumumab for KRAS G12C–Mutated mCRC: With Marwan Fakih, MD

marwan fda approval kras mutated mcrc

Play Episode Listen Later Mar 3, 2025 7:39

Dr Fakih discusses the significance of this approval, key findings from the pivotal CodeBreaK 300 trial (NCT05198934), and how this combination fits into the current KRAS G12C–mutated mCRC treatment paradigm.

S12 Ep19: FDA Approval Insights: T-DXd in HER2-Low/-Ultralow Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

medicine md fda mph md mph fda approval her2 metastatic breast cancer hematology oncology bardia fasco enhertu aditya bardia t dxd

Play Episode Listen Later Feb 27, 2025 7:20

In today's episode, we had the pleasure of speaking with Aditya Bardia, MD, MPH, FASCO, about the FDA approval of fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) for the treatment of adult patients with unresectable or metastatic, hormone receptor–positive, HER2-low or -ultralow breast cancer, as determined by an FDA-approved test, that has progressed on at least 1 endocrine therapy in the metastatic setting. Dr Bardia serves as a professor in the Department of Medicine in the Division of Hematology/Oncology and is the director of Translational Research Integration at the UCLA Health Jonsson Comprehensive Cancer Center. In our exclusive interview, Dr Bardia discussed the significance of this approval, findings from the pivotal DESTINY-Breast06 trial (NCT04494425), and what this new indication for T-DXd means for the future of HER2 testing in breast cancer.

Pharma and Biotech Daily: Navigating the Ever-Evolving Landscape

Play Episode Listen Later Feb 27, 2025 1:32

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.The Epic Act has been reintroduced in Congress to remove the IRA's 'pill penalty', with hopes for positive changes. However, budgetary constraints may make it challenging for the current administration to make significant amendments to the IRA. As money continues to flow into weight loss drugs, physicians are prioritizing efficacy and access. Emalex is moving towards FDA approval after a successful Phase III trial for Tourette Syndrome. AstraZeneca also received positive Phase III results for an oral breast cancer drug. SpringWorks Therapeutics successfully turned a Pfizer 'ghost drug' into a victory by keeping a rare disease program alive with the help of advocacy groups. This success story has led experts to believe that this method could be applied to other rare diseases as well. The company serves as a case study for how to mine biopharma's IP storeroom for rare disease drugs.Meanwhile, weight loss doctors are seeking better GLP-1 medications, but are facing challenges with high prices and supply issues. Trump is threatening big pharma with tariffs unless they reshore manufacturing. Bluebird Bio is facing financial challenges and may go private in a deal valued at $30 million. Compounders are suing the FDA over declaring a shortage of certain drugs, while the FTC is tightening merger rules despite the Trump administration's pro-industry stance.These updates show the ever-evolving landscape of the pharmaceutical and biotech industries. Stay tuned for more important news and developments in the field.

donald trump news navigating congress landscape fda evolving ip pfizer astrazeneca ftc pharma biotech glp fda approval tourette syndrome phase iii bluebird bio

Pharma and Biotech Daily: FDA Approves New Treatments and Collaborations in the Industry

Play Episode Listen Later Feb 24, 2025 3:09

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.##Title: Pfizer and BioNTech seek FDA approval for COVID-19 vaccine boosterPfizer and BioNTech have announced that they are seeking authorization from the FDA for a booster dose of their COVID-19 vaccine. The companies have presented data showing that a third dose of the vaccine can significantly increase protection against the Delta variant.##Title: Moderna to supply 100 million more doses of COVID-19 vaccine to the USModerna has reached an agreement with the US government to supply an additional 100 million doses of its COVID-19 vaccine. The company will deliver the doses by the end of the year, helping to boost vaccination efforts across the country.##Title: AstraZeneca's COVID-19 antibody treatment shows promising results in clinical trialsAstraZeneca has announced that its COVID-19 antibody treatment has shown promising results in clinical trials. The treatment, which is designed to prevent severe disease and hospitalization, could provide an important new tool in the fight against the virus.##Title: Novartis receives FDA approval for new treatment for advanced breast cancerNovartis has received FDA approval for a new treatment for advanced breast cancer. The drug, which targets a specific genetic mutation, has been shown to significantly improve progression-free survival in patients with the disease.##Title: Roche announces positive results from phase 3 trial of Alzheimer's drugRoche has announced positive results from a phase 3 trial of its Alzheimer's drug. The drug, which is designed to target the underlying cause of the disease, showed significant improvement in cognitive function and daily living activities in patients with early-stage Alzheimer's.##Title: Johnson & Johnson to invest $6.5 billion in expanding vaccine production capacityJohnson & Johnson has announced plans to invest $6.5 billion in expanding its vaccine production capacity. The company aims to increase production of its COVID-19 vaccine as well as other vaccines in its portfolio, helping to address global supply shortages.##Title: Merck receives FDA approval for new treatment for certain types of lung cancerMerck has received FDA approval for a new treatment for certain types of lung cancer. The drug, which targets a specific genetic mutation, has been shown to improve overall survival in patients with advanced disease.##Title: Gilead Sciences announces collaboration with Novartis on HIV researchGilead Sciences has announced a collaboration with Novartis on HIV research. The companies will work together to develop new treatments for HIV, with a focus on addressing drug resistance and improving outcomes for patients with the virus.## Title: Eli Lilly receives FDA approval for new treatment for migraineEli Lilly has received FDA approval for a new treatment for migraine. The drug, which is administered through an injection, has been shown to provide rapid relief from migraine symptoms and reduce the frequency of attacks in patients with the condition.

FDA Approval of Zolbetuximab SPOTLIGHT / GLOW study - Upper GI Cancer with Claudin 18.2 Mutation

Play Episode Listen Later Feb 21, 2025 22:37

In this episode of the Oncology Brothers podcast, Drs. Rahul and Rohit Gosain dive into the recent advancements in the treatment of gastroesophageal junction (GEJ) and gastric cancer, focusing on the newly approved drug Zolbetuximab. They are joined by Dr. Kohei Shitara, the lead author of the pivotal SPOTLIGHT study, who shared insights on the mechanism of action of Zolbetuximab, its clinical trial findings, and the implications for patient care. Key topics discussed include: •⁠ ⁠The mechanism of action of Zolbetuximab and its target, Claudin 18.2. •⁠ ⁠An overview of the GLOW and SPOTLIGHT studies, including study design and key findings on progression-free survival (PFS) and overall survival (OS). •⁠ ⁠Practical considerations for administering Zolbetuximab in clinical practice, including dosing schedules and side effect management. •⁠ ⁠The importance of testing for Claudin 18.2 and the challenges faced in rural settings without in-house testing. •⁠ ⁠Future directions in the treatment landscape for gastric cancer, including potential combination therapies and emerging agents. Join us for this informative discussion that highlights the changing standard of care in gastric cancer treatment and the exciting possibilities ahead for patients. Don't forget to like, share, and subscribe for more insightful conversations in the world of oncology! YouTube: https://youtu.be/BfpDHpqgHMs Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers

future study cancer practical os glow spotlight drs mutation rahul fda approval pfs upper gi

S12 Ep14: FDA Approval Insights: Dato-DXd for HR+/HER2-Negative Metastatic Breast Cancer: With Aditya Bardia, MD, MPH, FASCO

negative dato md mph fda approval her2 metastatic breast cancer bardia fasco aditya bardia

Play Episode Listen Later Feb 13, 2025 6:33

In our exclusive interview, Dr Bardia discussed the significance of this approval, pivotal findings from the phase 3 TROPION-Breast01 trial (NCT05104866), the clinical relevance of being able to improve progression-free survival and quality of life with Dato-DXd compared with standard chemotherapy, and key considerations for sequencing antibody-drug conjugates.

Understanding Ketamine Treatments with Dr. Banimahd

Addict II Athlete's podcast

Play Episode Listen Later Feb 11, 2025 54:30

In this episode of the Addict to Athlete podcast, Coach Blu Robinson welcomes Dr. Faried Banimahd to discuss the complexities of ketamine therapy in the context of mental health and addiction recovery. They explore the history of ketamine, its medical uses, particularly in pain management and mental health treatment, and the implications of its recent popularity as a therapeutic option. Dr. B provides insights into the mechanisms of ketamine, its FDA approval for treatment-resistant depression, and the importance of caution in its use, especially for individuals with a history of substance abuse. The conversation emphasizes the need for a comprehensive approach to mental health treatment, integrating therapy with any pharmacological interventions. In this conversation, Blu Robinson and Dr. Faried Banimahd delve into the complexities of psychedelics, particularly ketamine, and their potential therapeutic benefits for mental health. They discuss the risks associated with psychedelics, personal experiences, and the importance of controlled environments for treatment. The conversation also highlights the stigma surrounding these substances, the necessity of ongoing treatment, and the role of medical professionals in guiding patients through their mental health journeys. Ultimately, they emphasize the need for a multidimensional approach to treatment and the importance of understanding individual experiences within the broader healthcare system. Takeaways Ketamine is chemically related to PCP and has a history of abuse. It is used as a disassociative anesthetic in medical settings. Ketamine's role in pain management is significant, especially for chronic pain patients. The FDA has approved ketamine for treatment-resistant depression under specific protocols. Ketamine works by blocking NMDA receptors, affecting pain perception and mood. Long-term efficacy of ketamine therapy is still under research and not well established. Caution is advised for individuals with a history of substance abuse when considering ketamine therapy. Matthew Perry's case highlights the risks associated with unsupervised ketamine use. Therapy should be the first line of treatment for depression, even when using ketamine. Meaningful existence and self-development take time and should not be rushed. People with a history of severe bipolar and schizophrenia should be cautious with psychedelics. Psychedelics can awaken dormant psychological issues. Personal experiences with psychedelics can lead to significant insights and awareness. The perception of psychedelics as dangerous hinders their therapeutic potential. Therapeutic environments are crucial for the safe use of psychedelics. Dr. B YouTube · Dr.B36087.1K+ followersDr.B360 insta Instagram · getdrb2.4K+ followersAddiction Medicine (@getdrb) • Instagram photos and videos Please join Addict to Athlete's Patreon support page and help us turn the mess of addiction into the message of sobriety! https://www.patreon.com/addicttoathlete Please visit our website for more information on Team Addict to Athlete and Addiction Recovery Podcasts. https://www.AddictToAthlete.org Join the Team! Circle, our new social support event, along with the team and athlete communication platform, is designed to help us break free from doom scrolling and shadow banning and foster stronger connections among us. Follow the link, download the app, and start this new chapter of Team AIIA! Join Circle https://a2a.circle.so/join?invitation_token=16daaa0d9ecd7421d384dd05a461464ce149cc9e-63d4aa30-1a67-4120-ae12-124791dfb519

mental health personal depression team therapy addiction healthcare treatments circle risks fda psychedelics meaningful stigma addicts caution therapeutic substance abuse matthew perry ketamine pain management addiction recovery personal experience pcp fda approval hallucinogens nmda team addict addiction recovery podcasts

Pharma and Biotech Daily: The Latest in Industry News and Developments

Play Episode Listen Later Feb 10, 2025 1:08

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Eisai reports lagging sales of Leqembi in the US and is now looking towards gaining approval for a subcutaneous version. Novo Nordisk executives are trying to boost sentiment after the failure of obesity candidate Cagrisema, without providing hard numbers. Regeneron is suing Sanofi for allegedly withholding information about the sales of Dupixent. Nasdaq newcomers Acelyrin and Alumis have merged to focus on immune-mediated diseases. The AAPS National Biotechnology Conference will cover trends in research and biopharma markets.Equillium's Itolizumab is competing with Humira in ulcerative colitis. FDA approval of Vertex's non-opioid Jornavx signals a new era in pain treatment. Novo's bispecific for hemophilia has aced a phase III pediatric trial. Lilly has increased Zepbound supply, prompting analysts to question if it is sustainable. BMS has added $2 billion to cost-cutting plans and is eyeing deals after the success of Cobenfy. AstraZeneca has axed two Alexion assets as Q4 earnings exceed expectations.

news fda novo nasdaq astrazeneca developments pharma biotech sanofi novo nordisk vertex fda approval bms industry news regeneron zepbound humira eisai leqembi alexion dupixent

Unveiling Corruption in Alzheimer's Research, Part 1

Play Episode Listen Later Feb 4, 2025 32:48

Investigative journalist Charles Piller reveals deep-seated corruption in Alzheimer's research as chronicled in his book, “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's Disease.” The discussion delves into the issues surrounding Big Pharma's influence, fraudulent scientific studies, and the implications of a controversial 2006 experiment at the University of Minnesota. They also address the costly and marginally effective Alzheimer's drugs like Aducanumab, the challenges faced by alternative research hypotheses, and the significance of improving scientific integrity and checks and balances in medical research.

Unveiling Corruption in Alzheimer's Research, Part 2

Play Episode Listen Later Feb 4, 2025 26:02

Dr. Hoffman continues his conversation with investigative journalist Charles Piller, author of “Doctored: Fraud, Arrogance, and Tragedy in the Quest to Cure Alzheimer's Disease.”

FDA Approval of Subcutaneous Nivolumab CheckMate-67T - Subcutaneous Nivo vs. Intravenous (IV) Nivo

fda drs checkmate rohit fda approval intravenous subcutaneous nivolumab

Play Episode Listen Later Jan 31, 2025 15:04

Welcome to the Oncology Brothers Podcast! In this episode, Drs. Rohit and Rahul Gosain are joined by Dr. Saby George from Roswell Park Comprehensive Cancer Center to discuss the recent approval of subcutaneous nivolumab based on the CheckMate-67T study. Join us as we delve into: •⁠ ⁠The study design and findings of CheckMate-67T •⁠ ⁠The implications of subcutaneous nivolumab for patients and healthcare providers •⁠ ⁠Safety signals and side effects associated with the new formulation •⁠ ⁠The significant time savings for patients receiving treatment •⁠ ⁠Real-world experiences from patients involved in the trial This episode highlights how the subcutaneous formulation of nivolumab can enhance patient care by reducing time spent in infusion centers while maintaining efficacy and safety. Tune in to learn more about this exciting advancement in cancer treatment and its potential impact on patient quality of life! Don't forget to like, subscribe, and check out our other episodes for more insights on FDA drug approvals, conference highlights, and treatment algorithms. We are the Oncology Brothers! YouTube: https://youtu.be/4blP8jqizUQ Follow us on social media: •⁠ ⁠X/Twitter: https://twitter.com/oncbrothers •⁠ ⁠Instagram: https://www.instagram.com/oncbrothers Subscribe to our channel for more insights on oncology treatments and patient care!

Biotech Buzz: Updates on Lilly, Novo Nordisk, and FDA Changes

news fda buzz ozempic pharma robert f kennedy jr biotech novo nordisk kidney disease novavax fda approval relaxin

Play Episode Listen Later Jan 30, 2025 0:44

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world. Lilly has stopped a mid-stage study on relaxin for chronic kidney disease due to a lack of foreseeable clinical benefit, following the drug's failure in a related heart failure study. Meanwhile, Novo Nordisk's Ozempic has received FDA approval for kidney disease, expanding its use beyond diabetes and weight loss. The FDA may see changes under RFK Jr. and Makary, with concerns raised about Kennedy's vaccine-related views. BioAge has dropped an obesity asset after going public, I-Mab and Zentalis are cutting staff, and Novavax is seeking silver linings two years into a reset. Stay tuned for more updates in the biotech industry.

Episode 206 | Simon Malpas, Chief Executive Officer at Kitea Health | From Brain Pressure Implants to FDA Approval: Navigating the PMA Process for Medtech Startups

Project Medtech

Play Episode Listen Later Jan 21, 2025 37:18

In this episode, Simon Malpas, CEO of Kitea Health, joins Duane Mancini to share his incredible journey from blood pressure researcher to Medtech CEO. Simon details Kitea Health's innovative brain pressure implant, revealing the challenges and triumphs of navigating clinical trials and the FDA's PMA process as a startup.Hear firsthand accounts of Kitea's dedication – from attending every surgery during their pilot study to building a strong company culture. Simon discusses the critical role of fundraising, strategic planning, and execution in achieving success in the Medtech industry. Tune in for invaluable insights into leadership, perseverance, and the future of medical technology. Simon Malpas LinkedIn ⁠Kitea Health LinkedIn Kitea Health Website ⁠⁠⁠Duane Mancini LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Project Medtech LinkedIn⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Project Medtech Website ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠Midwest Showcase Registration⁠

ceo health navigating brain startups pressure fda chief executive officer chief executives implants pma medtech fda approval duane mancini

Treating Alzheimer's with Light and Sound - with Christian Howell | EP 194

The Empowering Neurologist Podcast

Play Episode Listen Later Jan 20, 2025 49:45

S12 Ep6: FDA Approval Insights: Subcutaneous Nivolumab for Advanced Solid Tumors: With Roxana S. Dronca, MD

md fda jacksonville internal medicine bristol myers squibb fda approval hematology oncology subcutaneous solid tumors nivolumab yervoy

Play Episode Listen Later Jan 20, 2025 10:56

In today's episode, supported by Bristol Myers Squibb, we had the pleasure of speaking with Roxana S. Dronca, MD, about the FDA approval of subcutaneous nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for advanced or metastatic solid tumors. Dr Dronca is a professor of oncology, a consultant in the Division of Hematology/Oncology in the Department of Internal Medicine, and director of the Mayo Clinic Comprehensive Cancer Center in Jacksonville, Florida. On December 27, 2024, the FDA approved subcutaneous nivolumab across approved adult, solid tumor nivolumab indications, including as monotherapy, monotherapy maintenance after completion of nivolumab in combination with ipilimumab (Yervoy), or in combination with cabozantinib (Cabometyx) or chemotherapy. This regulatory decision was backed by findings from the phase 3 CheckMate-67T trial (NCT04810078) and includes indications for melanoma, renal cell carcinoma, non–small cell lung cancer, urothelial carcinoma, head and neck squamous cell carcinoma, colorectal cancer, esophageal carcinoma, esophageal adenocarcinoma, hepatocellular carcinoma, gastric cancer, and gastroesophageal junction cancer. In our exclusive interview, Dr Dronca discussed the significance of this FDA approval across multiple solid tumor indications, pivotal findings from the CheckMate-67T trial, and how this approval represents a paradigm shift in modern cancer care delivery.

Nutrition Nugget: The Minnesota Starvation Experiment

Salad With a Side of Fries

Play Episode Listen Later Jan 3, 2025 15:02

Nutrition Nugget! Bite-size bonus episodes offer tips, tricks and approachable science. This week, Jenn is talking about the Minnesota Starvation Experiment. Conducted from 1944 to 1945, this clinical study explored the physical and psychological effects of semi-starvation and refeeding. While it's a historical study, its findings remain relevant today, particularly as we examine current health and weight-loss practices. Jenn dives into the participants' experiences, the dramatic impacts of calorie restriction, and what we can learn about achieving health goals sustainably, not through diets or restriction. Tune in for an eye-opening discussion that ties past research to modern challenges and solutions. Like what you're hearing? Be sure to check out the full-length episodes, new releases every Wednesday. Have an idea for a nutrition nugget? Submit it here: https://asaladwithasideoffries.com/index.php/contact/ RESOURCES:Learn more about Healthy Vibe Tribe on Jan 6 at 8pm ETReady to jump into the Healthy Vibe Tribe? Start here: Become A Member of Salad with a Side of FriesJenn's Free Menu PlanA Salad With a Side of FriesA Salad With A Side Of Fries MerchA Salad With a Side of Fries InstagramBirth Control, Part 1: FDA Approval and What Happened Next (feat. Mike Gaskins)Birth Control, Part 2: Ditching the Pill (feat. Rach Hoeppner)

Mesoblast CEO on FDA Approval, Development Pipeline

TD Ameritrade Network

Play Episode Listen Later Jan 3, 2025 6:55

Dr. Silviu Itescu, CEO of the biotech company Mesoblast (MESO), joins Market On Close. The company is developing therapeutics using stem cells to target severe inflammatory conditions, including pediatric conditions. He discusses Mesoblast's recent FDA approval for a cell therapy that is the first of its type, and its potential uses in bone marrow transplant patients. ======== Schwab Network ======== Empowering every investor and trader, every market day. Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribe Download the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185 Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7 Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watch Watch on Vizio - https://www.vizio.com/en/watchfreeplus-explore Watch on DistroTV - https://www.distro.tv/live/schwab-network/ Follow us on X – https://twitter.com/schwabnetwork Follow us on Facebook – https://www.facebook.com/schwabnetwork Follow us on LinkedIn - https://www.linkedin.com/company/schwab-network/ About Schwab Network - https://schwabnetwork.com/about

ceo development ios fda pipeline sling fda approval vizio market minute

FDA Approval of Zanidatamab - HERIZON-BTC-01 Discussion with Dr. Shubham Pant

Play Episode Listen Later Jan 2, 2025 17:15

Welcome to the Oncology Brothers podcast! In this episode, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of Zanidatamab, a bispecific HER2 antibody, for HER2 amplified, unresectable, locally advanced, or metastatic biliary tract cancer. Join us as we discuss the HERIZON-BTC-01 study with Dr. Shubham Pant, a GI medical oncologist at MD Anderson Cancer Center and one of the study's authors. We explore the significance of HER2 testing in biliary tract cancers, the study's design, key findings, and the implications for treatment strategies in the community oncology setting. Key topics include: • Overview of biliary tract cancer and its treatment landscape • Study design and patient characteristics from the HERIZON-BTC-01 trial • Key findings, including overall response rates and duration of response • The importance of HER2 testing and its implications for treatment sequencing • Side effect profiles and management strategies for Zanidatamab • Future directions and ongoing clinical trials Don't miss this insightful discussion that highlights the exciting advancements in HER2-targeted therapies for biliary tract cancer. Make sure to subscribe for more updates on recent FDA approvals, treatment algorithms, and conference highlights. We look forward to seeing you at GI ASCO 2025 in person! Website: http://www.oncbrothers.com/ X/Twitter: https://twitter.com/oncbrothers Contact us at info@oncbrothers.com

study fda gi drs rahul pant fda approval md anderson cancer center her2 shubham

S11 Ep49: FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD

new york md fda rna dor orr memorial sloan kettering cancer center fda approval pancreatic nsclc schram adenocarcinoma

Play Episode Listen Later Jan 2, 2025 5:59

In today's episode, supported by Merus, we had the pleasure of speaking with Alison Schram, MD, about the FDA approval of zenocutuzumab-zbco (Bizengri) for patients with previously treated advanced pancreatic adenocarcinoma or non–small cell lung cancer (NSCLC) harboring NRG1 gene fusions. Dr Schram is an assistant attending physician at Memorial Sloan Kettering Cancer Center in New York, New York. On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab for the treatment of adult patients with advanced, unresectable, or metastatic pancreatic adenocarcinoma harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy; and adult patients with advanced, unresectable, or metastatic NSCLC harboring an NRG1 gene fusion who have disease progression on or after prior systemic therapy. This regulatory decision was based on findings from the phase 2 eNRGy trial (NCT02912949), in which patients with pancreatic adenocarcinoma (n = 30) achieved an overall response rate (ORR) of 40% (95% CI, 23%-59%), and a duration of response (DOR) that ranged from 3.7 months to 16.6 months. In the NSCLC cohort (n = 64), the (ORR) of 33% (95% CI, 22%-46%), and the median DOR was 7.4 months (95% CI, 4.0-16.6). In our exclusive interview, Dr Schram discussed the significance of this approval, key efficacy data from the pancreatic cancer and NSCLC cohorts of eNRGy, and the importance of using RNA-based testing to identify patients with NRG1 fusions.

S11 Ep48: FDA Approval Insights: Zanidatamab in Pretreated, HER2+ Biliary Tract Cancer